pfizer oral glp 1 discontinues GLP-1 receptor agonist danuglipron Pfizer, Novo Nordisk bidding war

Non-abstinence outcomes in the coming RCTs should be the primary endpoints I think

ScienceDaily.com slapped this headline on it: The Guardian reported: Healthline.com reported: Using relative risk reduction figures almost always makes the benefit seem larger than it really is, and thereby misleads the general public

Mounjaro and Wegovy are similar

Although brain-specific STAT5 knockout mice exhibit memory deficits (37), suggesting a direct effect of the GHR-STAT5 signaling pathway in regulating memory (Figure 2), it is possible that GHR signaling stimulates local IGF-1 production

It requires daily dosing, compared to weekly dosing for semaglutide and tirzepatide